UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on investors.urogen.com
Leave the platform to read the original full article on the publisher site.
Source: UroGen Pharma
Scope: Industry
Related coverage
More related coverage
Internal linkProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
Located in Leiden, Netherlands and Cambridge, Mass., ProQR Therapeutics (Nasdaq:PRQR) is a clinical-...
Internal linkProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board
Located in Leiden, Netherlands and Cambridge, Mass., ProQR Therapeutics (Nasdaq:PRQR) is a clinical-...
Internal linkDownload presentation
Located in Leiden, Netherlands and Cambridge, Mass., ProQR Therapeutics (Nasdaq:PRQR) is a clinical-...
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinic...